Idiopathic Thrombocytopenic Purpura
Reference39 articles.
1. Arnold, D. M., Dentali, F., Crowther, M. A., et al. (2007). Systematic review: Efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Annals of Internal Medicine, 146(1), 25–33. 2. Blanchette, V., Imbach, P., Andrew, M., et al. (1994). Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet, 344, 703–707. 3. Brighton, T. A., Evans, S., Castaldi, P. A., Chesterman, C. N., & Chong, B. H. (1996). Prospective evaluation of the clinical usefulness of an antigen-specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias. Blood, 88, 194–201. 4. Catani, L., Fagioli, M. E., Tazzari, P. L., et al. (2006). Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. Experimental Hematology, 34(7), 879–887. 5. Cheng, Y., Wong, R. S. M., Soo, Y. O. Y., et al. (2003). Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. New England Journal of Medicine, 349, 831–836.
|
|